| Radiopharmaceutical Chemistry and Applications | Lifetime | 5 | CA 1 | 99.93 |
| Prostate Cancer Treatment and Research | Lifetime | 7 | CA 1 | 99.94 |
| Cancer Diagnosis and Treatment | Lifetime | 12 | CA 1 | 99.85 |
| Bone health and treatments | Lifetime | 13 | CA 1 | 99.89 |
| Cancer, Lipids, and Metabolism | Lifetime | 20 | CA 1 | 99.85 |
| Prostate Cancer Diagnosis and Treatment | Lifetime | 36 | CA 2 | 99.82 |
| Management of metastatic bone disease | Lifetime | 27 | CA 6 | 99.24 |
| PARP inhibition in cancer therapy | Lifetime | 30 | CA 3 | 99.46 |
| Hormonal and reproductive studies | Lifetime | 71 | CA 2 | 99.38 |
| Multiple Myeloma Research and Treatments | Lifetime | 125 | CA 4 | 99.12 |
| Medical Imaging and Pathology Studies | Lifetime | 344 | CA 13 | 98.07 |
| Bladder and Urothelial Cancer Treatments | Lifetime | 375 | CA 20 | 98.45 |
| Cancer Treatment and Pharmacology | Lifetime | 871 | CA 27 | 97.71 |
| Clusterin in disease pathology | Lifetime | 21 | CA 2 | 96.23 |
| Bone and Joint Diseases | Lifetime | 492 | CA 24 | 96.30 |
| Renal cell carcinoma treatment | Lifetime | 967 | CA 43 | 96.42 |
| Genital Health and Disease | Lifetime | 693 | CA 26 | 94.72 |
| Urinary and Genital Oncology Studies | Lifetime | 782 | CA 32 | 95.51 |
| NF-κB Signaling Pathways | Lifetime | 922 | CA 20 | 92.99 |
| Prostate Cancer Diagnosis and Treatment | 2021-2025 | 2 | CA 1 | 99.91 |
| Prostate Cancer Treatment and Research | 2021-2025 | 5 | CA 1 | 99.91 |
| Hormonal and reproductive studies | 2021-2025 | 4 | CA 1 | 99.66 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 8 | CA 1 | 99.79 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 16 | CA 1 | 99.47 |
| PARP inhibition in cancer therapy | 2021-2025 | 10 | CA 1 | 99.66 |
| Estrogen and related hormone effects | 2021-2025 | 20 | CA 1 | 97.50 |
| Bone health and treatments | 2021-2025 | 27 | CA 3 | 96.88 |
| Multiple Myeloma Research and Treatments | 2021-2025 | 269 | CA 10 | 96.30 |
| Statistical Methods in Clinical Trials | 2021-2025 | 95 | CA 7 | 92.08 |
| Bladder and Urothelial Cancer Treatments | 2021-2025 | 447 | CA 9 | 94.85 |
| Renal cell carcinoma treatment | 2021-2025 | 550 | CA 18 | 92.48 |
| Cancer Treatment and Pharmacology | 2021-2025 | 433 | CA 10 | 91.62 |
| DNA Repair Mechanisms | 2021-2025 | 327 | CA 10 | 88.85 |
| Urological Disorders and Treatments | 2021-2025 | 550 | CA 22 | 88.38 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 284 | CA 6 | 83.14 |
| Urinary and Genital Oncology Studies | 2021-2025 | 549 | CA 12 | 87.71 |
| Genital Health and Disease | 2021-2025 | 386 | CA 14 | 83.42 |
| Renal and related cancers | 2021-2025 | 943 | CA 35 | 81.08 |
| Cancer Diagnosis and Treatment | 2021-2025 | 803 | CA 25 | 75.70 |
| Urologic and reproductive health conditions | 2021-2025 | 573 | CA 21 | 79.65 |
| Management of metastatic bone disease | 2021-2025 | 771 | CA 54 | 73.60 |
| Cell death mechanisms and regulation | 2021-2025 | 347 | CA 5 | 65.17 |
| Testicular diseases and treatments | 2021-2025 | 788 | CA 33 | 62.93 |
| Infectious Disease Case Reports and Treatments | 2021-2025 | 141 | CA 3 | 52.07 |
